All In Biotech

Drug Trial Radar · NCT06220773

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

May 21, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

Conditions

  • Essential Hypertension
  • Type 2 Diabetes Mellitus

Interventions

  • BR1019ADrug

    Subjects take the investigational products once a day for 12 weeks.

  • BR1019BDrug

    Subjects take the investigational products once a day for 12 weeks.

  • BR1019CDrug

    Subjects take the investigational products once a day for 12 weeks.

  • BR1019A-1Drug

    Subjects take the investigational products once a day for 12 weeks.

  • BR1019B-1Drug

    Subjects take the investigational products once a day for 12 weeks.

  • BR1019C-1Drug

    Subjects take the investigational products once a day for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1Time frame: 12 weeks from Baseline Visit
  2. The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1Time frame: 12 weeks from Baseline Visit

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD)

    Jakarta, DKI Jakarta, Indonesia · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.